Skip to main content

Advertisement

SpringerLink
Log in

Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice—results of a non-representative survey

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

There is a growing evidence for over-, under-, or misuse of health care in patients with inflammatory bowel disease. Most studies looked at treatment variability or used quality measures, which mostly capture supportive interventions rather than treatment of IBD in itself. We aimed to evaluate if current recommendations in clinical practice guidelines regarding the medical treatment of patients with inflammatory bowel diseases are being followed in Germany.

Methods

A questionnaire was sent to 1901 patients insured with two large German statutory sickness funds and an ICD 10 diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC). The questionnaire asked about drug treatment, indications for drug treatment, provision of surveillance endoscopies in ulcerative colitis patients, and smoking status in Crohn’s disease patients.

Results

Out of 460 evaluable patients, 62.4% of UC patients and 53.9% of CD patients were treated with mesalamine according to guidelines, 91.3% of all patients were treated with glucocorticoids according to guideline recommendations, while only 75.6% received recommended immunosuppressive treatment. Of UC patients, 94.5% had surveillance colonoscopies at the recommended interval and 58.8% of CD patients were non-smokers. No predictor for overall treatment according to guidelines could be found while being of age older than 60 or being treated outside of a dedicated IBD clinic was associated with less immunosuppressive treatment.

Conclusions

A large proportion of patients with IBD do not receive drug treatment in accordance with clinical practice guidelines. Quality improvement measures are much needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dignass A, Preiß JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger K, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann J, Stallmach A (2011) Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 - Ergebnisse einer Evidenzbasierten Konsensuskonferenz. Z Gastroenterol 49:1276–1341. https://doi.org/10.1055/s-0031-1281666

    Article  CAS  PubMed  Google Scholar 

  2. Preiß JC, Bokemeyer B, Buhr HJ, Dignaß A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, Siegmund B, Stallmach A, Stange EF, Stein J, Hoffmann JC, German Society of Gastroenterology (2014) Aktualisierte S3-Leitlinie - “Diagnostik und Therapie des Morbus Crohn” 2014. Z Gastroenterol 52:1431–1484. https://doi.org/10.1055/s-0034-1385199

    Article  PubMed  Google Scholar 

  3. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, for the European Crohn’s and Colitis Organisation [ECCO] (2017) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, Cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670. https://doi.org/10.1093/ecco-jcc/jjx008

    Article  PubMed  Google Scholar 

  4. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, for the European Crohn’s and Colitis Organisation [ECCO] (2017) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis 11:769–784. https://doi.org/10.1093/ecco-jcc/jjx009

    Article  PubMed  Google Scholar 

  5. Gomollón F, Dignass A, Annese V, Tilg H, van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, on behalf of ECCO (2017) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11:3–25. https://doi.org/10.1093/ecco-jcc/jjw168

    Article  PubMed  Google Scholar 

  6. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, Laureti S, Sampietro GM, Vucelic B, van der Woude CJ, Barreiro-de Acosta M, Maaser C, Portela F, Vavricka SR, Gomollón F, on behalf of ECCO (2017) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: part 2: surgical management and special situations. J Crohns Colitis 11:135–149. https://doi.org/10.1093/ecco-jcc/jjw169

    Article  PubMed  Google Scholar 

  7. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18:496–505. https://doi.org/10.1002/ibd.21719

    Article  PubMed  Google Scholar 

  8. Mawdsley JED, Irving PM, Makins RJ, Rampton DS (2006) Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol 18:249–253

    Article  PubMed  Google Scholar 

  9. Kirchgatterer A, Wenzl HH, Aschl G, Hinterreiter M, Stadler B, Hinterleitner TA, Petritsch W, Knoflach P (2002) Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med Austriaca 29:120–123

    Article  CAS  PubMed  Google Scholar 

  10. Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC (2013) Physicians’ perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci 58:46–52. https://doi.org/10.1007/s10620-012-2435-6

    Article  CAS  PubMed  Google Scholar 

  11. Tinsley A, Naymagon S, Trindade AJ, Sachar DB, Sands BE, Ullman TA (2013) A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 47:e1–e6. https://doi.org/10.1097/MCG.0b013e31824c0dea

    Article  CAS  PubMed  Google Scholar 

  12. Nguyen GC, Murthy SK, Bressler B, Lam MCW, Alali A, Toumi A, Reinglas J, Rampersad A, Weizman AV, Afif W (2017) Quality of care and outcomes among hospitalized inflammatory bowel disease patients: a multicenter retrospective study. Inflamm Bowel Dis 23:695–701. https://doi.org/10.1097/MIB.0000000000001068

    Article  PubMed  Google Scholar 

  13. Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJS (2008) Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 14:253–258. https://doi.org/10.1002/ibd.20266

    Article  PubMed  Google Scholar 

  14. Long MD, Porter CQ, Sandler RS, Kappelman MD (2009) Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 7:549–553. https://doi.org/10.1016/j.cgh.2008.10.007

    Article  PubMed  Google Scholar 

  15. Chevaux J-B, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L (2010) Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 16:916–924. https://doi.org/10.1002/ibd.21147

    Article  PubMed  Google Scholar 

  16. Teich N, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, Schiefke I (2011) Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int 108:105–111. https://doi.org/10.3238/arztebl.2011.0105

    Article  PubMed  PubMed Central  Google Scholar 

  17. Spiegel BMR, Ho W, Esrailian E, Targan S, Higgins PDR, Siegel CA, Dubinsky M, Melmed GY (2009) Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 7:168–174, 174.e1. https://doi.org/10.1016/j.cgh.2008.08.029

    Article  PubMed  Google Scholar 

  18. Hinojosa J, Gisbert JP, Gomollón F, López San Román A (2012) Adherence of gastroenterologists to European Crohn’s and colitis organisation consensus on Crohn’s disease: a real-life survey in Spain. J Crohns Colitis 6:763–770. https://doi.org/10.1016/j.crohns.2011.12.013

    Article  CAS  PubMed  Google Scholar 

  19. Caldera F, Saha S, Wald A, Cooley DM, Zhao YQ, Li Z, Bartels CM (2016) Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home. Expert Rev Gastroenterol Hepatol 10:759–766. https://doi.org/10.1586/17474124.2016.1169920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sawczenko A, Lynn R, Sandhu BK (2003) Variations in initial assessment and management of inflammatory bowel disease across Great Britain and Ireland. Arch Dis Child 88:990–994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, Kihn R, Pfaff R, Orlemann S, Schaeffer R, Schröder O, Digna A, Hartmann F, Stein J (2008) Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm Bowel Dis 14:53–60. https://doi.org/10.1002/ibd.20257

    Article  CAS  PubMed  Google Scholar 

  22. Magro F, Barreiro-de Acosta M, Lago P, Carpio D, Cotter J, Echarri A, Gonçalves R, Pereira S, Carvalho L, Lorenzo A, Barros L, Castro J, Dias JA, Rodrigues S, Portela F, Dias C, da Costa-Pereira A, EIGA, GEDII (2010) Clinical practice in Crohn’s disease in bordering regions of two countries: different medical options, distinct surgical events. J Crohns Colitis 4:301–311. https://doi.org/10.1016/j.crohns.2009.12.004

    Article  PubMed  Google Scholar 

  23. Ananthakrishnan AN, Kwon J, Raffals L, Sands B, Stenson WF, McGovern D, Kwon JH, Rheaume RL, Sandler RS (2015) Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol 13:1197–1200. https://doi.org/10.1016/j.cgh.2014.11.020

    Article  PubMed  Google Scholar 

  24. Hilsden RJ, Verhoef MJ, Best A, Pocobelli G (2003) A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol 3:10. https://doi.org/10.1186/1471-230X-3-10

    Article  PubMed  PubMed Central  Google Scholar 

  25. Blumenstein I, Bock H, Zosel C, Dignass A, Hartmann F, Zeuzem S, Stein J, Schroeder O (2009) Gibt es geschlechtsspezifische Behandlungsunterschiede bei Patienten mit chronisch entzündlichen Darmerkrankungen? Eine Subgruppenanalyse einer prospektiven, multizentrischen, online-basierten Studie. Z Gastroenterol 47:1045–1051. https://doi.org/10.1055/s-0028-1109647

    Article  CAS  PubMed  Google Scholar 

  26. Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, Dignaß A, Hartmann F, Zeuzem S, Stein J, Schröder O (2011) Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 5:203–210. https://doi.org/10.1016/j.crohns.2010.12.012

    Article  CAS  PubMed  Google Scholar 

  27. Nguyen GC, LaVeist TA, Harris ML et al (2010) Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol 105:2202–2208. https://doi.org/10.1038/ajg.2010.202

    Article  PubMed  PubMed Central  Google Scholar 

  28. Donovan M, Lunney K, Carter-Pokras O, Cross RK (2007) Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 52:1798–1805. https://doi.org/10.1007/s10620-006-9269-z

    Article  CAS  PubMed  Google Scholar 

  29. Farraye FA, Waye JD, Moscandrew M, Heeren TC, Odze RD (2007) Variability in the diagnosis and management of adenoma-like and non-adenoma-like dysplasia-associated lesions or masses in inflammatory bowel disease: an internet-based study. Gastrointest Endosc 66:519–529. https://doi.org/10.1016/j.gie.2006.12.016

    Article  PubMed  Google Scholar 

  30. Yeung JH, Goodman KJ, Fedorak RN (2012) Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis 18:34–40. https://doi.org/10.1002/ibd.21668

    Article  PubMed  Google Scholar 

  31. Wasan SK, Coukos JA, Farraye FA (2011) Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 17:2536–2540. https://doi.org/10.1002/ibd.21667

    Article  PubMed  Google Scholar 

  32. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D (1999) Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care 11:187–192

    Article  CAS  PubMed  Google Scholar 

  33. Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, Radford-Smith G, Selby W, Veillard AS, Grimm MC, Travis SPL, Lawrance IC (2013) Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 7:e449–e456. https://doi.org/10.1016/j.crohns.2013.02.019

    Article  CAS  PubMed  Google Scholar 

  34. Stange EF, Schreiber S, Fölsch UR, von Herbay A, Schölmerich J, Hoffmann J, Zeitz M, Fleig WE, Buhr HJ, Kroesen AJ, Moser G, Matthes H, Adler G, Reinshagen M, Stein J, German Society for Digestive and Metabolic Diseases (2003) Diagnostik und Therapie des M. Crohn – Ergebnisse einer evidenzbasierten konsensuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 41:19–20. https://doi.org/10.1055/s-2003-36661

    Article  CAS  PubMed  Google Scholar 

  35. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, Dignaß A, Fischer I, Fleig W, Fölsch UR, Herrlinger K, Höhne W, Jantschek G, Kaltz B, Keller KM, Knebel U, Kroesen AJ, Kruis W, Matthes H, Moser G, Mundt S, Pox C, Reinshagen M, Reißmann A, Riemann J, Rogler G, Schmiegel W, Schölmerich J, Schreiber S, Schwandner O, Selbmann HK, Stange EF, Utzig M, Wittekind C (2004) Diagnostik und Therapie der Colitis Ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen zusammen mit dem Kompetenznetz chronisch entzündliche Darmerkrankungen. Z Gastroenterol 42:979–983

    Article  CAS  PubMed  Google Scholar 

  36. Travis SP, Stange EF, Lemann M et al (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 55(Suppl 1):i16–i35

    Article  PubMed  PubMed Central  Google Scholar 

  37. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Schölmerich J, Reinisch W, European Crohn’s and Colitis Organisation (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 55(Suppl 1):i1–i15

    Article  PubMed  PubMed Central  Google Scholar 

  38. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O’Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ, European Crohn’s and Colitis Organisation (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut 55(Suppl 1):i36–i58

    Article  PubMed  PubMed Central  Google Scholar 

  39. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF, European Crohn’s and Colitis Organisation (ECCO) (2008) European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2:1–23. https://doi.org/10.1016/j.crohns.2007.11.001

    Article  CAS  PubMed  Google Scholar 

  40. Travis SPL, Stange EF, Lemann M et al (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2:24–62. https://doi.org/10.1016/j.crohns.2007.11.002

    Article  CAS  PubMed  Google Scholar 

  41. Biancone L, Michetti P, Travis SPL, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E, European Crohn’s and Colitis Organisation (ECCO) (2008) European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2:63–92. https://doi.org/10.1016/j.crohns.2007.12.001

    Article  PubMed  Google Scholar 

  42. Loftus EV (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517. https://doi.org/10.1053/j.gastro.2004.01.063

    Article  PubMed  Google Scholar 

  43. Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G (2018) Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390:2779–2789. https://doi.org/10.1016/S0140-6736(17)32641-7

    Article  PubMed  Google Scholar 

  44. Kaltz B, Bokemeyer B, Hoffmann J, Porschen R, Rogler G, Schmiegel W (2007) Überwachungskoloskopie bei Colitis ulcerosa in Deutschland. Z Gastroenterol 45:325–331. https://doi.org/10.1055/s-2007-962987

    Article  CAS  PubMed  Google Scholar 

  45. van Rijn AF, Fockens P, Siersema PD, Oldenburg B (2009) Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn’s colitis patients in the Netherlands. World J Gastroenterol 15:226–230

    Article  PubMed  PubMed Central  Google Scholar 

  46. Siu AL (2015) Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 163:622–634. https://doi.org/10.7326/M15-2023

    Article  PubMed  Google Scholar 

  47. Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka SR, Rogler G, for the Swiss Inflammatory Bowel Disease Cohort Study Group (2015) High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation--data from the Swiss IBD Cohort Study. J Crohns Colitis 9:819–829. https://doi.org/10.1093/ecco-jcc/jjv113

    Article  PubMed  Google Scholar 

  48. Miller DR, Rogers WH, Kazis LE, Spiro A III, Ren XS, Haffer SC (2008) Patients’ self-report of diseases in the Medicare Health Outcomes Survey based on comparisons with linked survey and medical data from the Veterans Health Administration. J Ambul Care Manage 31:161–177. https://doi.org/10.1097/01.JAC.0000314707.88160.9c

    Article  PubMed  Google Scholar 

  49. Gama H, Correia S, Lunet N (2009) Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 18:175–187. https://doi.org/10.1002/pds.1703

    Article  PubMed  Google Scholar 

  50. Kappelman MD, Palmer L, Boyle BM, Rubin DT (2010) Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis 16:125–133. https://doi.org/10.1002/ibd.21028

    Article  PubMed  Google Scholar 

  51. Rubin G, Hungin APS, Chinn D, Dwarakanath AD, Green L, Bates J (2002) Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 16:1889–1893

    Article  CAS  PubMed  Google Scholar 

  52. Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR (2007) 5-Aminosalicylic acid (mesalazine) use in Crohn’s disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 13:1009–1015. https://doi.org/10.1002/ibd.20135

    Article  PubMed  Google Scholar 

  53. Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA (2005) Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 100:1357–1361. https://doi.org/10.1111/j.1572-0241.2005.40849.x

    Article  PubMed  Google Scholar 

  54. Zhu Q, Cao Q, Si J-M (2008) Quality of care for patients with inflammatory bowel disease in East China. World J Gastroenterol 14:612–616

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the support by the three involved sickness funds, AOK Nordost (Katrin Peise), TK (Christine Vietor), and AOK Rheinland/Hamburg (Markus Feger) as well as Annegret Schönberg for secretarial assistance.

Funding agency

This study was partially funded by the Ministry of Education and Research (Bundesministerium für Bildung und Forschung), Germany, through the Kompetenznetz Entzündliche Darmerkrankungen (Grant Number 01 GI 0486).

Author information

Authors and Affiliations

  1. Medizinische Klinik m. S. Gastroenterologie, Infektiologie und Rheumatologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12200, Berlin, Germany

    Lea I. Kredel, Oliver Schneidereit, Jörg C. Hoffmann, Britta Siegmund & Jan C. Preiß

  2. Klink für Anästhesie, Segeberger Kliniken, Bad Segeberg, Germany

    Oliver Schneidereit

  3. Medizinische Klinik I, St. Marienkrankenhaus, Ludwigshafen, Germany

    Jörg C. Hoffmann

  4. Klinik für Innere Medizin – Gastroenterologie, Diabetologie und Hepatologie, Vivantes Klinikum Neukölln, Berlin, Germany

    Jan C. Preiß

Authors
  1. Lea I. Kredel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Schneidereit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg C. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Britta Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan C. Preiß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan C. Preiß.

Ethics declarations

Conflict of interest

JCH served as consultant for Astra, Falk, Hexal, Janssen, Pfizer, Steigerwald, and Takeda, and received lecture fees from Falk, Janssen, MSD, Pfizer, and Takeda. BS received a research grant from Pfizer, served as consultant for Falk, Janssen, MSD, Abbvie, Celgene, Lilly, Takeda, Pfizer, and Hospira and received lecture fees from Abbvie, Falk, Ferring, Janssen, MSD, Merck, and Takeda; all money went to the Charité-Universitätsmedizin Berlin, Germany. JCP served as a consultant for MSD, Pfizer, Takeda, and Biogen and received lecture fees from Vifor, Falk, Janssen, Abbvie, Pfizer, Vifor, MSD, and Takeda.

Ethical approval

The local ethics board approved the protocol. All patient-related data were anonymized after open questions had been resolved in responders who provided their contact information.

Informed consent

Informed consent was assumed if patients sent in their questionnaire. The local data protection commissioner approved the protocol.

Additional information

Wolfgang Höhne and Martin Zeitz are deceased; the manuscript is dedicated to them.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kredel, L.I., Schneidereit, O., Hoffmann, J.C. et al. Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice—results of a non-representative survey. Int J Colorectal Dis 34, 431–440 (2019). https://doi.org/10.1007/s00384-018-3215-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-018-3215-3

Keywords

Search

Navigation